NO20010284L - Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP) - Google Patents

Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP)

Info

Publication number
NO20010284L
NO20010284L NO20010284A NO20010284A NO20010284L NO 20010284 L NO20010284 L NO 20010284L NO 20010284 A NO20010284 A NO 20010284A NO 20010284 A NO20010284 A NO 20010284A NO 20010284 L NO20010284 L NO 20010284L
Authority
NO
Norway
Prior art keywords
disease
pacap
adenylate cyclase
activating polypeptide
pituitary adenylate
Prior art date
Application number
NO20010284A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010284D0 (no
Inventor
Zheng Xin Dong
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NO20010284D0 publication Critical patent/NO20010284D0/no
Publication of NO20010284L publication Critical patent/NO20010284L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NO20010284A 1998-07-20 2001-01-17 Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP) NO20010284L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11954098A 1998-07-20 1998-07-20
PCT/EP1999/003020 WO2000005260A1 (en) 1998-07-20 1999-04-30 Peptide analogues of pacap

Publications (2)

Publication Number Publication Date
NO20010284D0 NO20010284D0 (no) 2001-01-17
NO20010284L true NO20010284L (no) 2001-03-19

Family

ID=22384966

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010284A NO20010284L (no) 1998-07-20 2001-01-17 Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP)

Country Status (15)

Country Link
EP (2) EP2161282A1 (da)
JP (2) JP2002521390A (da)
AR (1) AR019131A1 (da)
AT (1) ATE449789T1 (da)
AU (1) AU3826899A (da)
CA (1) CA2335341A1 (da)
CZ (1) CZ2001253A3 (da)
DE (1) DE69941708D1 (da)
DK (1) DK1098906T3 (da)
ES (1) ES2335827T3 (da)
HU (1) HUP0104934A3 (da)
NO (1) NO20010284L (da)
PL (1) PL345583A1 (da)
TW (1) TWI221845B (da)
WO (1) WO2000005260A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972319B1 (en) 1999-09-28 2005-12-06 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
AU7726600A (en) * 1999-09-28 2001-04-30 Bayer Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
AU2249701A (en) 1999-11-12 2001-06-06 David Bernstein Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use
US6608174B1 (en) 2000-02-18 2003-08-19 Dabur Research Foundation Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
AU2000265051A1 (en) * 2000-02-18 2001-08-27 Dabur Research Foundation Vasoactive intestinal peptide analogs
CN1487952A (zh) 2000-11-28 2004-04-07 �ɶ����＼��ʵ���� 具有血管活性肠肽的生物学活性的用于治疗肺动脉和小动脉高压的化合物
JP2002293799A (ja) * 2001-03-29 2002-10-09 Itoham Foods Inc 新規ペプチド及びそれを含有する消化管運動抑制剤
WO2003018782A2 (en) * 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
WO2003024472A2 (en) * 2001-09-14 2003-03-27 Stem Cell Therapeutics Inc. Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
AU2003228050A1 (en) * 2002-05-03 2003-11-17 Neuronova Ab Therapeutic use of PACAP, Maxadilan, PACAP receptor agonist and/or ADCYAP1R1 in the treatment of CNS disorders
CA2488358A1 (en) * 2002-06-10 2003-12-18 Mondobiotech Laboratories Anstalt Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
AU2003250705A1 (en) 2002-07-31 2004-02-16 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
WO2004062684A2 (en) 2003-01-16 2004-07-29 D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven Treatment of thrombocytopenia with inhibitors of pacap
JP4990634B2 (ja) 2004-02-13 2012-08-01 ステム セル セラピューティクス コーポレイション 神経幹細胞の増殖および神経発生のための黄体化ホルモン（ＬＨ）、および絨毛性ゴナドトロピン（ｈＣＧ）の使用
US7595294B2 (en) * 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
JP2006306770A (ja) * 2005-04-27 2006-11-09 Nidek Co Ltd 眼疾患治療剤
CA2664629A1 (en) 2005-09-27 2007-04-05 Christopher Gregg Oligodendrocyte precursor cell proliferation regulated by prolactin
EP1942941A1 (en) 2005-10-26 2008-07-16 Eli Lilly And Company Selective vpac2 receptor peptide agonists
EP2496245B1 (en) * 2009-11-02 2016-07-20 The Administrators Of The Tulane Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CN105377287A (zh) * 2013-02-15 2016-03-02 托马斯杰弗逊大学 用于肿瘤成像的试剂盒
WO2014144632A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Human pac1 antibodies
EP3019184A4 (en) * 2013-06-07 2017-04-05 The Administrators of the Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
WO2015023890A1 (en) * 2013-08-14 2015-02-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
EP3086846B1 (en) * 2013-12-27 2019-02-20 Dignity Health Diagnosing alzheimer's disease
EP3194435A1 (en) 2014-09-15 2017-07-26 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
EP3390447A1 (en) 2015-12-15 2018-10-24 Amgen Inc. Pacap antibodies and uses thereof
AU2017273857B2 (en) 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds
AU2018205458A1 (en) 2017-01-05 2019-07-11 The Regents Of The University Of California PAC1 receptor agonists (MAXCAPS) and uses thereof
KR20200110362A (ko) 2018-01-12 2020-09-23 암젠 인크 Pac1 항체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS277405B6 (en) * 1986-06-12 1993-03-17 Vyzk Ustav Farm Biochem Sp Peptides with 1-amino-1-cycloalkane carboxylic acid
US5128242A (en) * 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5623050A (en) * 1991-08-22 1997-04-22 Takeda Chemical Industries, Ltd. Stable polypeptides having c-AMP production enhancing activity and the use thereof
JP3354173B2 (ja) * 1991-08-22 2002-12-09 武田薬品工業株式会社 ポリペプチドおよびその用途
WO1996009318A1 (en) * 1994-09-22 1996-03-28 The Administrators Of The Tulane Educational Fund Method and pharmaceutical composition for prevention and treatment of brain damage
AU5441096A (en) * 1995-04-14 1996-10-30 The Administrators Of The Tulane Eductional Fund Analogs of growth hormone-releasing factor
US5753206A (en) * 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
DE69630583T2 (de) * 1995-06-09 2004-09-30 Itoham Foods Inc., Kobe Peptide, bronchodilator und den blutstrom verbesserndes mittel
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
AU6846196A (en) * 1995-08-15 1997-03-12 International Software Machines Programmable compiler

Also Published As

Publication number Publication date
PL345583A1 (en) 2001-12-17
ES2335827T3 (es) 2010-04-05
AU3826899A (en) 2000-02-14
AR019131A1 (es) 2001-12-26
WO2000005260A1 (en) 2000-02-03
NO20010284D0 (no) 2001-01-17
CZ2001253A3 (cs) 2001-11-14
TWI221845B (en) 2004-10-11
ATE449789T1 (de) 2009-12-15
HUP0104934A3 (en) 2002-05-28
EP1098906B1 (en) 2009-11-25
JP2002521390A (ja) 2002-07-16
JP2010189398A (ja) 2010-09-02
CA2335341A1 (en) 2000-02-03
DE69941708D1 (de) 2010-01-07
HUP0104934A2 (hu) 2002-04-29
EP1098906A1 (en) 2001-05-16
DK1098906T3 (da) 2010-03-29
EP2161282A1 (en) 2010-03-10

Similar Documents

Publication Publication Date Title
NO20010284L (no) Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP)
Hirose et al. N-acyl 6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist
Cabrele et al. Molecular characterization of the ligand–receptor interaction of the neuropeptide Y family
US9200037B2 (en) Compounds for control of appetite
CN1950342B (zh) 作为阿片受体调节剂的新化合物
CA2162924A1 (en) New peptide antagonists at glutamate and nmda receptors
US8299023B2 (en) Neuropeptide-2 receptor (Y-2R) agonists
PT94160B (pt) Processo para preparacao de derivados de alfa-aminocarboxamidas n-fenilalquil substituidas e composicoes farmaceuticas que os contem
Kaga et al. Emerging functions of neuropeptide Y Y2 receptors in the brain
CA2318800A1 (en) Fluorine-containing amino acid derivatives
JPH10504569A (ja) 向代謝性グルタメート受容体拮抗剤としてのピロリジニルジカルボン酸誘導体
WO2002005748A3 (en) Medicinal uses of mu-opioid receptor agonists
US10487087B2 (en) Positive allosteric modulators of the GLP-1 receptor
JPS63258894A (ja) アミノ酸誘導体
EP1116727A4 (en) PEPTIDE DERIVATIVE
Mashal et al. The effects of cholecystokinin on dopaminergic mechanisms in rat striatum
DE602004010529T2 (de) 2-amino-5-benzoylthiazol npy-antagonisten
NZ332829A (en) Use of a polypeptide corresponding to a serine threonine kinase receptor, ALK-7 for neurological diseases
Meena et al. Synthesis of CNS active thyrotropin-releasing hormone (TRH)-like peptides: Biological evaluation and effect on cognitive impairment induced by cerebral ischemia in mice
Blommaert et al. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor
US6417159B1 (en) Method of enhancing effect of a neurotrophin with analogues of p75NTR367-379.
WO2020109526A3 (en) Oxyntomodulin peptide analog formulations
Dolbeare et al. iso-Lactam and reduced amide analogues of the peptidomimetic dopamine receptor modulator 3 (R)-[(2 (S)-Pyrrolidinylcarbonyl) amino]-2-oxo-1-pyrrolidineacetamide
Gottschlich et al. EMD 61 753 as a favourable representative of structurally novel arylacetamido-type K opiate receptor agonists
WO2004083867A3 (en) Modulators of g protein-coupled formyl peptide receptor-like 2 and their therapeutic use against cell death-related disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application